4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

Core Viewpoint - 4D Molecular Therapeutics aims to redefine genetic medicines by developing durable disease-targeted therapeutics for large market diseases, with a primary focus on their lead product, 4D-150, currently in Phase III trials for wet AMD [2][3]. Development Focus - The primary focus of 4D Molecular Therapeutics is on 4D-150, which is in Phase III trials for wet AMD, with positive progress reported in the pivotal trial [3]. - The company plans to initiate a Phase III trial for diabetic macular edema later this year, building on Phase II results [2][3]. Additional Assets - In addition to the retina program, 4D Molecular Therapeutics is developing assets in pulmonology, specifically 4D-710 and 4D-725, which are fully funded through support from the CF Foundation and a grant from CIRM [4].